Use of drug-eluting stents for patients with coronary heart disease

Justice, Jessica; Yacono, Christian S

doi:10.1097/01720610-200908000-00009

Cited by 6 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…paclitaxel, sirolimus, and the more recent zotarolimus and everolimus) [31] have been incorporated in the stent and gradually released, showed another long-term side-effect with respect to BMS, consisting in a delayed re-endothelialization after angioplasty, which leads to an excessive cell proliferation in the vascular wall and to thrombosis, thus requiring a more effective anti-platelet therapy [32].…”

Section: Polyamine Synthesis and Functionsmentioning

confidence: 99%

The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis

Forte¹,

Hellstrand²,

Nilsson³

et al. 2011

CVP

View full text Add to dashboard Cite

Section: Polyamine Synthesis and Functionsmentioning

confidence: 99%

The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis

Forte¹,

Hellstrand²,

Nilsson³

et al. 2011

CVP

View full text Add to dashboard Cite

“…Moreover, constrictive remodelling can also still occur in the presence of a stent in regions distal or proximal to the stented segment. The main reason is that DES were responsible for another long-term side effect with respect to BMS, consisting of delayed re-endothelialization after angioplasty and leading to excessive cell proliferation in the vascular wall and to thrombosis, thus requiring more effective anti-platelet therapy [11]. Nonetheless, DES only reduced by 50 % the need for target vessel revascularization with respect to BMS [10].…”

Section: Main Revascularization Procedures In Patientsmentioning

confidence: 99%

Novel potential targets for prevention of arterial restenosis: insights from the pre-clinical research

et al. 2014

View full text Add to dashboard Cite

Restenosis is the pathophysiological process occurring in 10-15% of patients submitted to revascularization procedures of coronary, carotid and peripheral arteries. It can be considered as an excessive healing reaction of the vascular wall subjected to arterial/venous bypass graft interposition, endarterectomy or angioplasty. The advent of bare metal stents, drug-eluting stents and of the more recent drug-eluting balloons, have significantly reduced, but not eliminated, the incidence of restenosis, which remains a clinically relevant problem. Biomedical research in pre-clinical animal models of (re)stenosis, despite its limitations, has contributed enormously to the identification of processes involved in restenosis progression, going well beyond the initial dogma of a primarily proliferative disease. Although the main molecular and cellular mechanisms underlying restenosis have been well described, new signalling molecules and cell types controlling the progress of restenosis are continuously being discovered. In particular, microRNAs and vascular progenitor cells have recently been shown to play a key role in this pathophysiological process. In addition, the advanced highly sensitive high-throughput analyses of molecular alterations at the transcriptome, proteome and metabolome levels occurring in injured vessels in animal models of disease and in human specimens serve as a basis to identify novel potential therapeutic targets for restenosis. Molecular analyses are also contributing to the identification of reliable circulating biomarkers predictive of post-interventional restenosis in patients, which could be potentially helpful in the establishment of an early diagnosis and therapy. The present review summarizes the most recent and promising therapeutic strategies identified in experimental models of (re)stenosis and potentially translatable to patients subjected to revascularization procedures.

show abstract

“…Вместе с тем, отмечено, что снижение КЖ в определенной степени связано и с неблагоприятным клиническим исходом [19]. Однако, на наш взгляд, критерием эффективности примененных процедур должно быть повышение КЖ не только при краткосрочном, но и при отдаленном наблюдении [15] [12,13,18,29]. Авторы из Нидерландов приводят результаты сравнения таких процедур реваскуляризации [26].…”

unclassified

Omparison of Life Quality Parameters in the Remote Period of Interventional Treatment of Patients With Ischemic Heart Disease

Evtyukhin¹,

Ryazanova²,

Dedov³

et al. 2015

СПНО (MPSE)

View full text Add to dashboard Cite

Государственное бюджетное учреждение здравоохранения Тверской области «Областной клинический кардиологический диспансер», Тверь, Россия Представлен научный обзор зарубежных и российских публикаций по исследованию качества жизни больных ишемической болезнью сердца. В обзоре проведено сравнение уже полученных данных при оптимальной медикаментозной терапии и интервенционном лечении: аорто-коронарном шунтировании и чрескожном коронарном вмешательстве. Показана зависимость характеристик качества жизни от выраженности симптомов стабильной стенокардии. Отражены гендерные особенности параметров качества жизни при длительном наблюдении. Выявлена связь между качеством жизни и возрастом, полом, методом лечения. Подчеркивается актуальность учета клинических данных конкретного больного. В обзоре выполнен анализ качества жизни в ближайшем и отдаленном периоде наблюдения. Делается заключение, что тактика лечения должна определяться уменьшением частоты приступов стабильной стенокардии, повышением качества жизни и улучшением прогноза больных Ключевые слова: качество жизни, ишемическая болезнь сердца, отдаленное наблюдение

show abstract

Use of drug-eluting stents for patients with coronary heart disease

Cited by 6 publications

References 13 publications

The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis

The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis

Novel potential targets for prevention of arterial restenosis: insights from the pre-clinical research

Omparison of Life Quality Parameters in the Remote Period of Interventional Treatment of Patients With Ischemic Heart Disease

Contact Info

Product

Resources

About